Neurology
Charcot-Marie-Tooth Disease Type 1a
3
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Charcot-Marie-Tooth disease type 1A is an early-stage landscape with 3 programs across 3 companies. The most active players are AbbVie, Tasly GeneNet Pharmaceuticals Co., Ltd, McGuff Pharmaceuticals, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
3
clinical trials
Completed2 · 67%
Unknown status1 · 33%
Clinical Trials
Trial Activity
Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
Unknown status·—·Phase 3·NCT03023540·187 enrolled
Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
Completed·—·Phase 2·NCT01401257·80 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)